Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Noor Al-DasooqiRachel J. GibsonDorothy M. Keefe Mini Review 21 March 2009 Pages: 1 - 9
Treatment of metastatic renal cell carcinoma David J. ReevesChin Y. Liu Mini Review 03 April 2009 Pages: 11 - 25
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma Sun Jin SymDae Ho LeeCheolwon Suh Original Article 07 October 2008 Pages: 27 - 33
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor S. HarmsenI. MeijermanJ. H. M. Schellens Original Article Open access 07 October 2008 Pages: 35 - 43
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies Steven AttiaSherry Morgan-MeadowsGlenn Liu Original Article 08 October 2008 Pages: 45 - 51
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models Ute HochJennifer LynchJeffrey A. Silverman Original Article 19 October 2008 Pages: 53 - 65
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients Emilio BajettaMaria Di BartolomeoMargherita Galassi Original Article 21 October 2008 Pages: 67 - 72
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer Kiyoshi MoriHiroyuki KobayashiTetsuro Kodama Original Article 22 October 2008 Pages: 73 - 78
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors Jill KolesarWei HuangGeorge Wilding Original Article 22 October 2008 Pages: 79 - 86
Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form Beom Soo ShinHyoung Jun KimSun Dong Yoo Original Article 22 October 2008 Pages: 87 - 94
Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form Beom Soo ShinHyoung Jun KimSun Dong Yoo Erratum 28 February 2009 Pages: 95 - 96
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects Ricardo Nalda-MolinaBelén ValenzuelaJuan Jose Perez-Ruixo Original Article 22 October 2008 Pages: 97 - 108
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma Masahiro KanayamaHidenari NagaiYasukiyo Sumino Original Article 01 November 2008 Pages: 109 - 114
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Corine EkhartSjoerd RodenhuisAlwin D. R. Huitema Original Article Open access 07 November 2008 Pages: 115 - 122
Irinotecan-induced mucositis is associated with changes in intestinal mucins Andrea M. StringerRachel J. GibsonDorothy M. K. Keefe Original Article 08 November 2008 Pages: 123 - 132
Role of copper transporters in resistance to platinating agents Cara A. RabikEdward B. MaryonM. Eileen Dolan Original Article 08 November 2008 Pages: 133 - 142
Anticancer activities of sesquiterpene lactones from Cyathocline purpurea in vitro Guoyi MaLi ChongMartin H. N. Tattersall Original Article 09 November 2008 Pages: 143 - 152
Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice Dorleta OtaeguiAlicia Rodríguez-GascónJosé Luis Pedraz Original Article 11 November 2008 Pages: 153 - 159
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma Kevin B. KimWen-Jen HwuPatrick Hwu Original Article 11 November 2008 Pages: 161 - 167
Intrathoracic injection of paclitaxel for a patient with stage IV serous ovarian cancer: a case report Takashi MitamuraMasayoshi HosakaNoriaki Sakuragi Clinical Trial Report 18 February 2009 Pages: 169 - 170
Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study Patrick D. BeauchesneL. TaillandierC. Carnin Clinical Trial Report 08 April 2009 Pages: 171 - 175
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report Anubha BharthuarLori EgloffRenuka V. Iyer Short Communication 31 December 2008 Pages: 177 - 181
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents Erica L. WoodahlMatthew H. CrouthamelRodney J. Y. Ho Short Communication 04 January 2009 Pages: 183 - 188
To widen the setting of cancer patients who could benefit from metronomic capecitabine Margherita NanniniElisabetta NobiliGuido Biasco Short Communication 17 January 2009 Pages: 189 - 193
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? Massimo BrecciaAnna Maria FrustaciGiuliana Alimena Short Communication 21 January 2009 Pages: 195 - 197
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer Sara N. RichterMatteo NadaiGiorgio Palù Letter to the Editor 14 March 2009 Pages: 199 - 200
Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs? Sarah ThomassetNicole TellerAndreas J. Gescher Commentary 18 March 2009 Pages: 201 - 211
